HIMS' post-earnings revenue and net profit turned negative, with on-chain price once plummeting by 10%

BlockBeats news, November 10: Hims & Hers has today released its third-quarter financial results. The company's quarterly revenue increased by 49% year-over-year to $890 million, but gross margin declined from 74% last year to 57%, and net profit shifted from a gain of $15.8 million to a loss of $33 million. Profit guidance has also been downgraded. The company has revised its full-year adjusted EBITDA forecast for 2026 from the previous range of $275 million to $325 million down to $257 million to $277 million, with the midpoint decreasing by approximately 11%. Full-year revenue guidance has been narrowed to $3.13 billion to $3.15 billion. According to TradingBeats monitoring, after the earnings release, a significant spike occurred in HIMS perpetual contracts on Hyperliquid. Around 05:08, the trading price dropped sharply to $20.57, a decline of about 10.4% from the $22.95 prior to the announcement; it then quickly rebounded and returned above $23 within about half an hour. As of this report, the contract is trading at approximately $22.14, down about 14.8% over the past 24 hours, still about 3.6% lower than before the earnings announcement; meanwhile, trading volume reached around $11.43 million, with notional value of open interest at approximately $3.22 million. In contrast, Moderna contracts rose by about 5.9% to $271.66 during the same period. Moderna reported third-quarter net profit of approximately $162 million on November 6 and upgraded its full-year revenue growth forecast from no more than 10% to 15%-25%.